Key facts
- It has raised $16.6M across 3 recorded rounds; the latest was Seed Round ($2.2M) in Nov 2024.
- Notable investors include MedTech Innovator, National Institutes of Health, East Carolina University, Lung, National Heart — 7 tracked in total.
- Perfusio has filed 3 Form Ds with the SEC since 2021, most recently Dec 2024 ($2.2M sold to 36 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Perfusio
Funding rounds
3 roundsAbout Perfusio
Developer of a blood-flow imaging device designed to verify blood flow and offer real-time assessment of tissue integrity and medical imaging. The company's device shows real-time blood flow and perfusion in vascular structures and critical tissues during surgeries by visualizing patient hemoglobin flows to reduce procedural complications or repeat surgeries, enabling doctors to improve clinical outcomes for patients, lessening discomfort and stress by reducing hospital costs.
- Sector
- Healthcare
- HQ
- Greenville, NC, United States
- Founded
- 2014
- Employees
- 6
- Website
- perfusio.com/
- Ownership
- Privately Held (backing)
Perfusio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Perfusio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Perfusio in its N-PORT filings yet. We sweep new filings monthly.